ClinicalTrialsFinder

High Risk Non-Muscle Invasive Bladder Urothelial Carcinoma Clinical Trials in Sacramento, California

1 recruitingSacramento, California

Showing 1–1 of 1 trials

Recruiting
Phase 1

IDO and PD-L1 Peptide Based Immune-Modulatory Therapeutic (IO102-IO103) in Combination With Pembrolizumab for BCG-Unresponsive or Intolerant, Non-Muscle Invasive Bladder Cancer

Stage 0a Bladder Cancer AJCC v8Stage 0is Bladder Cancer AJCC v8Stage I Bladder Cancer AJCC v8+1 more
University of California, Davis30 enrolled1 locationNCT05843448